Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 7/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.53 |
| ▸ | SRC | P12931 | 6/20 | 0.53 |
| ▸ | SIK1 | P57059 | 2/20 | 0.52 |
| ▸ | SIK2 | Q9H0K1 | 2/20 | 0.52 |
| ▸ | SIK3 | Q9Y2K2 | 2/20 | 0.52 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.50 |
| ▸ | WEE1 | P30291 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.49 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.49 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.49 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.48 |
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4509325 | 0.95 | PAK1 (0.54) | PAK1EGFRALKSRCSIK1 | |
| SCHEMBL4496375 | 0.93 | SRC (0.57) | PAK1EGFRALKSRCSIK1 | |
| SCHEMBL4493407 | 0.91 | SIK1 (0.63) | PAK1EGFRSRCSIK1SIK2 | |
| SCHEMBL4508084 | 0.91 | PAK1 (0.54) | PAK1EGFRALKSRCSIK1 | |
| SCHEMBL4506989 | 0.90 | LCK (0.58) | PAK1EGFRALKSRCSIK1 | |
| SCHEMBL4497423 | 0.89 | PAK1 (0.55) | PAK1EGFRALKSRCSIK1 | |
| SCHEMBL4497239 | 0.89 | LCK (0.61) | EGFRSRCLCKJAK3BTK | |
| SCHEMBL4501072 | 0.89 | PAK1 (0.53) | PAK1EGFRALKSRCSIK1 | |
| SCHEMBL4495553 | 0.89 | SIK1 (0.61) | PAK1EGFRALKSRCSIK1 | |
| SCHEMBL4487403 | 0.87 | SIK1 (0.60) | PAK1EGFRALKSRCSIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | claimed |
| US-7504396-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-03-17 | — | — | US | disclosed |
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209221-A1 | Substituted heterocyclic compounds and methods of use | ICOS, CD4, HLA-DRB1 | PAK1 403/4885EGFR 2918/4885ALK 4437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.